The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis

Background: Tumor mutational burden (TMB) is a genomic biomarker that can predict favorable responses to immune checkpoint inhibitors (ICIs). Although we have better understanding of TMB in cancer immunity and cancer immunotherapy, the relationship between TMB and the clinical efficacy of ICIs remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Biao, Liu, Yixin, Wang, Miao, Li, Yi, Xu, Tianzi, Wei, Yongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959431/
https://www.ncbi.nlm.nih.gov/pubmed/35355708
http://dx.doi.org/10.3389/fphar.2022.748674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959431/
https://www.ncbi.nlm.nih.gov/pubmed/35355708
http://dx.doi.org/10.3389/fphar.2022.748674

Ejemplares similares